R Scott Pearsall

Summary

Publications

  1. pmc A soluble activin type IIA receptor induces bone formation and improves skeletal integrity
    R Scott Pearsall
    Acceleron Pharma, Inc, 149 Sidney Street, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 105:7082-7. 2008
  2. pmc Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth
    Roselyne Castonguay
    Acceleron Pharma, Cambridge, Massachusetts 02139, USA
    J Biol Chem 286:30034-46. 2011
  3. pmc Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb
    Dianne Sako
    Acceleron Pharma, Cambridge, MA 02139, USA
    J Biol Chem 285:21037-48. 2010
  4. pmc Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type
    Samuel M Cadena
    Acceleron Pharma Inc, 128 Sidney St, Cambridge, MA 02139, USA
    J Appl Physiol 109:635-42. 2010
  5. doi request reprint ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth
    Dianne Mitchell
    Acceleron Pharma, Cambridge, MA 02139, USA
    Mol Cancer Ther 9:379-88. 2010
  6. ncbi request reprint Identification of MAGI-3 as a transforming growth factor-alpha tail binding protein
    Jeffrey L Franklin
    Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Exp Cell Res 303:457-70. 2005

Collaborators

  • Mary Bouxsein
  • ERNESTO M CANALIS
  • Ravindra Kumar
  • Roselyne Castonguay
  • Kathryn W Underwood
  • Dianne Sako
  • Jasbir Seehra
  • Asya V Grinberg
  • Travis E Monnell
  • Nicolas Solban
  • Aaron W Mulivor
  • Dianne Mitchell
  • Kathleen N Tomkinson
  • Eileen G Pobre
  • Jeffrey A Ucran
  • Samuel M Cadena
  • Jeffrey L Franklin
  • Robert G Matthews
  • Eleonora Presman
  • Eric D Werner
  • Monique V Davies
  • Amy J Andreucci
  • June Liu
  • Matthew S Spaits
  • Erik Martinez-Hackert
  • Jennifer L Lachey
  • Silas Maniatis
  • Robert J Coffey
  • Loice Jeyakumar
  • Katherine S Meise
  • David Threadgill
  • Peter J Dempsey
  • Kenta Yoshiura
  • Galina Bogatcheva

Detail Information

Publications6

  1. pmc A soluble activin type IIA receptor induces bone formation and improves skeletal integrity
    R Scott Pearsall
    Acceleron Pharma, Inc, 149 Sidney Street, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 105:7082-7. 2008
    ..These observations support the development of this pharmacological strategy for the treatment of diseases with skeletal fragility...
  2. pmc Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth
    Roselyne Castonguay
    Acceleron Pharma, Cambridge, Massachusetts 02139, USA
    J Biol Chem 286:30034-46. 2011
    ..Together our findings indicate an important role of soluble endoglin ECD in the regulation of angiogenesis and highlight efficacy of endoglin-Fc as a potential anti-angiogenesis therapeutic agent...
  3. pmc Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb
    Dianne Sako
    Acceleron Pharma, Cambridge, MA 02139, USA
    J Biol Chem 285:21037-48. 2010
    ..Together, our findings reveal binding specificity and activity determinants of the ActRIIB receptor that combine to effect specificity in the activation of distinct signaling pathways...
  4. pmc Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type
    Samuel M Cadena
    Acceleron Pharma Inc, 128 Sidney St, Cambridge, MA 02139, USA
    J Appl Physiol 109:635-42. 2010
    ..Future studies should be undertaken to confirm that the observed effects are not age dependent or due to the relatively short study duration...
  5. doi request reprint ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth
    Dianne Mitchell
    Acceleron Pharma, Cambridge, MA 02139, USA
    Mol Cancer Ther 9:379-88. 2010
    ..These data show the efficacy of chimeric ALK1-Fc proteins in mitigating vessel formation and support the view that ALK1-Fc is a powerful antiangiogenic agent capable of blocking vascularization...
  6. ncbi request reprint Identification of MAGI-3 as a transforming growth factor-alpha tail binding protein
    Jeffrey L Franklin
    Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Exp Cell Res 303:457-70. 2005
    ....